- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Tafinlar
Synonyms :
dabrafenib
Class :
Antineoplastics and BRAF Kinase Inhibitor
150
mg
Oral
twice a day
Capsule
Continue the therapy until disease progression or unacceptable effects occur
150
mg
Oral
twice a day
Capsule
The dose can be taken either as single agent or in combination with trametinib Continue the therapy until disease progression or unacceptable effects occur
It may increase the serum concentration of Dabrafenib
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may enhance the serum concentration of CYP3A4 inhibitors
It may diminish the effect when combined with lumateperone by affecting CYP3A4 metabolism
may have an increased QTc-prolonging effect when combined with dabrafenib
It may diminish the effect when combined with efavirenz affecting CYP3A4 metabolism
when both drugs are combined, there may be an increased effect of cabozantinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increased level of serum concentration of alpelisib
when both drugs are combined, there may be a reduced effect of abemaciclib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
QTc interval is increased both by lenvatinib and dabrafenib
the effect of dabrafenib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
when both drugs are combined, there may be a reduced level or effect of romidepsin by affecting hepatic or intestinal enzyme cyp3a4 metabolism
it decreases the effect or level of palbociclib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
it decreases by affecting the hepatic enzyme CYP3A4 metabolism
may have an increased QTc-prolonging effect when combined with dabrafenib
may have an increased QTc-prolonging effect when combined with dabrafenib
may have an increased QTc-prolonging effect when combined with dabrafenib
may have an increased QTc-prolonging effect when combined with dabrafenib
when both drugs combine dabrafenib will increase the effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
cyclophosphamide effect of action decreased by affecting enzyme CYP3A4 metabolism
when both drugs are combined, there may be an increased metabolism of dabrafenib
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
when both drugs are combined, there may be a decreased level or effect of imatinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
decrease the serum level of docetaxel by affecting CYP3A4
trametinib may increase the adverse effects in some cases. dose modification may require
decrease the serum level of erdafitinib by affecting CYP3A4
CYP3A4 inhibitors increase the concentration of dabrafenib in serum
Adverse drug reactions:
Frequency defined
>10%
Hyperglycemia
Hypophosphatemia
Hyperkeratosis
Headache
Arthralgia
Papilloma
Alopecia
Increased alkaline phosphatase
Rash
Back pain
Cough
Myalgia
Constipation
1-10%
Cutaneous squamous cell carcinoma
Nasopharyngitis
Hyponatremia
Cutaneous squamous cell carcinoma
Pancreatitis
Hypersensitivity manifesting
Pregnancy warnings:
Breastfeeding warnings:
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first trimester or the later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: dabrafenib (Rx)
Pronounced: Da-bRAF-e-nib
Why do we use abrafenib?
dabrafenib is an anti-neoplastic drug used as its mesylate salt in the treatment of metastatic melanoma
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
